Xanax XR Articles
Azur buys four drugs from UCB
19 January 2009
DEA block to US e-Rx adoption set to end
30 June 2008
Illegal California pharmacy faces charges
2 June 2008
McKesson settles with DEA on lifestyle drugs
12 May 2008
FD-combo drugs taken off Indian market
10 September 2007
UK parliamentary c'tee surveys Rx drug abuse
30 July 2007
Web Rx drugs: "complex and emerging problem"
23 July 2007
Rx drug abuse rise provokes state action
16 July 2007
Bogus Canadian web pharmacy's death probe
2 April 2007
US FDA warns about misrepresented drugs bought over the Internet
26 February 2007
Alexza gets $50M investment for R&D
11 December 2006
US counterfeit drug scam used Internet spam
9 October 2006
Schwarz beats 1st-half expectations
8 August 2005
Generics "can be dearer in Canada than USA"
26 January 2004
US push for generics of "gold-standard" drugs
25 February 2002
Third-party payers lead Rx payments
5 May 1999
Pharmacia & Upjohn sells last Spanish plant
23 February 1999
HMO Stops Supplying Zantac, Xanax, Mevacor
8 December 1998
P&U Taken To Court Over Xanax
26 March 1998
P&U 1997 Sales Slide, Earnings Hit By Charges
18 February 1998
Stricter Controls For Benzodiazepines In USA?
18 September 1997
Net Income Falls At Pharmacia & Upjohn
12 August 1996
Paxil Approved For Panic Disorder In USA
13 May 1996
Pharmacia & Upjohn First Combined Results
26 February 1996
Antidepressant Growth "Well Above Average"
22 January 1996
Seroxat In 1st Major Market For Panic
27 November 1995
Upjohn Turning A Corner?
24 July 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Two More Launches For Upjohn's Freedox
24 April 1995
First Approval For Upjohn's Freedox
13 March 1995
End Of Year Encouraging For US Companies
6 February 1995
Upjohn's Lazaroid Drug Runs Into Trouble
9 January 1995
Generic Drug Stocks - A Buying Opportunity
22 August 1994
US Biotech Cos Top Earnings At 1st Half
25 July 1994
WEST POINT EXPANDS PRODUCT LINE
9 May 1994
RESTRUCTURING AND GENERICS HIT UPJOHN
25 April 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
UPJOHN OUTLINES STRATEGIC DIRECTIONS
18 April 1994
R-PR ANXIOLYTIC FOR INTERNEURON
28 February 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
WORLD MARKETS FOR CNS AND GASTROINTESTINALS
13 December 1993
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
CYGNUS TO FILE FOR ALPRAZOLAM PATCH
23 August 1993
BRIGHT FUTURE FOR HEALTH CARE AT SOLVAY
12 July 1993
HHS RECOMMENDATIONS FOR ANTIDEPRESSANTS
3 May 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
UPJOHN PACT WITH GENEVA EXTENDED
5 April 1993
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
RISK YEARS AHEAD FOR UPJOHNFOR UPJOHN
22 March 1993
WORLD CNS MARKET IS LARGE AND FRAGMENTED
22 February 1993
GENERIC HALCION AND XANAX IN USA
1 February 1993
SOLVAY'S HEALTH CARE BUSINESS REVIEWED
25 January 1993
US/CANADA DRUG PRICE STUDY "MISLEADING"
2 November 1992
UPJOHN REVISES EARNINGS OUTLOOK
29 June 1992
UPJOHN'S GLYNASE APPROVED IN USA
27 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
RECORD 4TH QTR FROM US DRUG COMPANIES
10 February 1992
Showing 1-65 of 65 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
